"Hydrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substituted derivatives of hydrazine (formula H2N-NH2).
| Descriptor ID |
D006834
|
| MeSH Number(s) |
D02.442
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrazines".
Below are MeSH descriptors whose meaning is more specific than "Hydrazines".
This graph shows the total number of publications written about "Hydrazines" by people in this website by year, and whether "Hydrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 4 | 6 |
| 2020 | 2 | 1 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrazines" by people in Profiles.
-
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells. Cancer Res. 2024 01 02; 84(1):101-117.
-
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206.
-
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.
-
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.
-
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407.
-
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019 07 10; 7(1):175.
-
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
-
Commonly used FRET fluorophores promote collapse of an otherwise disordered protein. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):8889-8894.
-
Quantitative Mapping of Endosomal DNA Processing by Single Molecule Counting. Angew Chem Int Ed Engl. 2019 03 04; 58(10):3073-3076.
-
Deacylative transformations of ketones via aromatization-promoted C-C bond activation. Nature. 2019 03; 567(7748):373-378.